Table 4 LFTs results and clinical evaluation at three months
Parameters | Normal range | Overall (39) | CT improving at 3 month (31) | CT not improving at 3 month (8) | P value |
|---|---|---|---|---|---|
FEV 1 (l) (mean ± SD) | 2.9 ± 0.7 | 3.0 ± 0.7 | 2.6 ± 0.7 | 0.045 | |
FEV 1 (% ± SD) | 93.4 ± 16.1 | 95.1 ± 14.8 | 89.6 ± 15.6 | 0.52 | |
FVC (l) (mean ± SD) | 3.7 ± 0.9 | 3.8 ± 0.9 | 3.5 ± 1.1 | 0.97 | |
Obstruction (n and %) | 3 (7.7) | 1 (3.2) | 2 (25) | 0.10 | |
Restriction (n and %) | 3 (7.7) | 2 (6.5) | 1 (12.5) | 0.50 | |
Abnormal DLCO (n and %) | 22 (56.4) | 18 (58.1) | 4 (50) | 0.71 | |
DLCO (%, mean ± SD) | > 75 | 71.3 ± 15.5 | 70.5 ± 11.5 | 74.1 ± 26.5 | 0.62 |
LFTs abnormalities (n and %) | 25 (64.1) | 20 (64.6) | 5 (62.5) | 1 | |
6MWT (m, mean ± SD) | 539.3 ± 102.8 | 545.8 ± 96.6 | 514 ± 134.1 | 0.33 | |
SpO2 at rest at 3 month (%, mean ± SD) | 95–100 | 95.6 ± 1.6 | 95.7 ± 1.7 | 95 ± 1.2 | 0.10 |
SpO2 effort at 3 month (%, mean ± SD) | 95–100 | 91.3 ± 3.5 | 91.2 ± 3.9 | 91.4 ± 1.9 | 0.43 |
mMRC score (≥ 2) at 3 month (n and %) | 6 (15.4) | 4 (12.9) | 2 (25) | 0.58 |